Clinical Trials Logo

Warm Autoimmune Hemolytic Anemia clinical trials

View clinical trials related to Warm Autoimmune Hemolytic Anemia.

Filter by:

NCT ID: NCT03226678 Completed - Clinical trials for Warm Autoimmune Hemolytic Anemia

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Start date: August 31, 2017
Phase: Phase 2
Study type: Interventional

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

NCT ID: NCT03075878 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Start date: January 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.

NCT ID: NCT01181154 Completed - Clinical trials for Warm Autoimmune Hemolytic Anemia

Rituximab in Auto-Immune Hemolytic Anemia

RAHIA
Start date: March 3, 2011
Phase: Phase 3
Study type: Interventional

The hypothesis based on retrospective data is that, the rate of overall response-rate (PR + CR) at 1 year will be much higher in the rituximab arm (80%) than in the placebo arm (20%).Thirty four patients (17 in each arm) will be include (amendment n°6 - 15/10/2013) over a 3 year period (amendment n°3 - 11/12/2012).